BNTX Stock Selloff Deepens Doubts: BMO Ties BNT113 Miss To Wider mRNA Cancer Vaccine Struggles

BMO Capital Markets analyst Evan David Seigerman said that the PFS miss for BNT113 “adds to a growing list of recent mRNA cancer vaccine setbacks” and is likely to pressure the stock.
Read the full report on Asianet Newsable
Story file
- Section
- Health
- Topics
- Health alerts
- First reported by
- Asianet Newsable
- Reporter
- stocktwits inc
- Published
- Wednesday, 14 October 2026, 5:00 am IST
- Coverage
- One outlet so far
How this page works. The Headline Update lists this report from Asianet Newsable with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.

